<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

[ X ]    Quarterly  Report  pursuant to Section 13 or 15(d) of the Securities
         Exchange  Act  of  1934

         For  the  quarterly  period  ended  February  28,  2003

[   ]    Transition  Report  pursuant to 13 or 15(d) of the Securities Exchange
         Act  of  1934

         For  the  transition  period              to


            Commission  File  Number          000-33389
                                              ---------

                          AUGUST BIOMEDICAL CORPORATION
          -----------------------------------------------------------------
          (Exact name of small Business Issuer as specified in its charter)

NEVADA                                    52-2268239
-------------------------------           ----------
(State or other jurisdiction of           (IRS Employer
incorporation  or  organization)          Identification No.)

SUITE L-8, 601 W. BROADWAY
VANCOUVER, BRITISH COLUMBIA, CANADA       V5Z  4C2
------------------------------------      ------------
(Address of principal executive offices)  (Zip  Code)

Issuer's telephone number, including area code:     (604)  608-3831
                                                    ---------------

                         COYOTE  VENTURES  CORP.
                         -----------------------
              (Former name, former address and former fiscal year,
                          if changed since last report)

Check  whether  the issuer (1) filed all reports required to be filed by Section
13  or  15(d)  of  the  Securities  Exchange Act of 1934 during the preceding 12
months  (or  for  such  shorter period that the issuer was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days  [  X  ]  Yes    [  ]  No

State the number of shares outstanding of each of the issuer's classes of common
stock,  as  of  the  latest  practicable date: 12,065,000 Shares of Common Stock
outstanding  as  of  February  28,  2003.

<PAGE>


                         PART 1 - FINANCIAL INFORMATION

Item  1.          Financial  Statements

The  accompanying  un-audited  financial  statements  have  been  prepared  in
accordance  with  the instructions to Form 10-QSB and, therefore, do not include
all information and footnotes necessary for a complete presentation of financial
position,  results  of  operations,  cash  flows,  and  stockholders' deficit in
conformity  with  generally  accepted  accounting principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results  of  operations  and  financial position have been included and all such
adjustments  are  of  a  normal recurring nature.  Operating results for the six
months  ended  February  28,  2003 are not necessarily indicative of the results
that  can  be  expected  for  the  year  ending  August  31,  2003.

                                       2

<PAGE>






                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)


                    CONSOLIDATED INTERIM FINANCIAL STATEMENTS


                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)










                                       3

<PAGE>


                          AUGUST BIOMEDICAL CORPORATION

                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

                       CONSOLIDATED INTERIM BALANCE SHEET
                            (Stated in U.S. Dollars)


<TABLE>
<CAPTION>


---------------------------------------------------------
                                  FEBRUARY 28   AUGUST 31
                                     2003         2002
---------------------------------------------------------
                                  (Unaudited)   (Audited)
<S>                               <C>         <C>
ASSETS

Current
  Cash                            $  79,777   $ 183,608
  Advances receivable                 1,500           -
  Prepaid expenses                      622       1,554
                                  ----------------------

                                     81,899     185,162
Equipment (Note 4)                   24,418      10,991
Intangible Assets (Note 5)          220,000      20,000
                                  ----------------------

                                  $ 326,317   $ 216,153
========================================================




LIABILITIES

Current
  Accounts payable and accrued
   liabilities                    $  27,495   $  49,591
  Loan payable (Note 6)             180,000           -
                                  ----------------------


                                    207,495      49,591
Share Subscriptions Received         20,000           -
                                  ----------------------


                                    227,495      49,591
                                  ----------------------



STOCKHOLDERS' EQUITY

Capital Stock
  Authorized:
   100,000,000 Common shares,
    par value $0.001 per share

  Issued and outstanding:
   12,065,000 Common shares          12,065      12,025

  Additional paid-in capital        517,935     417,975

Deficit Accumulated During
The Development Stage              (431,178)   (183,278)
                                  ----------------------
                                     98,822     246,722
Less:  Subscriptions Receivable           -     (80,160)
                                  ----------------------


                                     98,822     166,562
                                  ----------------------

                                  $ 326,317   $ 216,153
========================================================


Nature Of Operations (Note 2)
</TABLE>


                                       4

<PAGE>





                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

                     CONSOLIDATED INTERIM STATEMENT OF LOSS
                                   (Unaudited)
                            (Stated in U.S. Dollars)


<TABLE>
<CAPTION>

                                                                          INCEPTION
                                                                            MAY 26
                             THREE MONTHS ENDED        SIX MONTHS ENDED     2000 TO
                              FEBRUARY 28                FEBRUARY 28      FEBRUARY 28
                         2003          2002          2003          2002        2003
--------------------------------------------------------------------------------------
<S>                  <C>           <C>           <C>           <C>           <C>

Expenses
  Amortization       $     1,082   $         -   $     1,998   $         -   $  3,329
  Consulting fees         83,481         3,800       134,387        16,800    177,823
  General and
   administrative          4,357           433        23,187           846     35,258
  Investor relations       3,368             -        23,500             -     26,690
  Mineral property
   option payments             -        10,000             -        10,000     15,500
  Mineral property
   exploration
   expenditures                -             -             -         4,000     12,273
  Professional fees       30,323        11,626        61,702        15,423    154,945
  Stock transfer fees      2,327             -         3,126             -      5,359
                     -----------------------------------------------------------------
Net Loss For
The Period           $   124,938   $    25,859   $   247,900   $    47,069   $431,178
======================================================================================
Basic And Diluted
Loss Per Share       $     (0.01)  $     (0.01)  $     (0.02)  $     (0.01)
===========================================================================
Weighted Average
Number of Shares
Outstanding           12,030,555    11,575,000    12,027,762    11,575,000
===========================================================================

</TABLE>



                                       5


<PAGE>



                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

                  CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
                                   (Unaudited)
                            (Stated in U.S. Dollars)




<TABLE>
<CAPTION>


                                      --------------------------------------------------------
                                                                                    INCEPTION
                                                                                      MAY 26
                                       THREE MONTHS ENDED     SIX MONTHS ENDED       2000 TO
                                           FEBRUARY 28           FEBRUARY 28        FEBRUARY 28
                                         2003       2002        2003       2002        2003
                                      --------------------------------------------------------
<S>                                   <C>         <C>        <C>         <C>        <C>

Cash Flows From Operating Activities
  Net loss for the period             $(124,938)  $(25,859)  $(247,900)  $(47,069)  $(431,178)
  Item not involving cash:
  Amortization                            1,082          -       1,998          -       3,329
Adjustments To Reconcile Net
 Loss To Net Cash Used By
 Operating Activities
  Prepaid expenses                          466          -         932          -        (622)
  Advances receivable                         -          -      (1,500)         -      (1,500)
  Accounts payable and
   accrued liabilities                   (9,095)    15,059     (22,096)    16,105      27,495
                                      --------------------------------------------------------
                                       (132,485)   (10,800)   (268,566)   (30,964)   (402,476)
                                      --------------------------------------------------------

Cash Flows From
Financing Activities
  Share capital issued                  100,000          -     180,160          -     530,000
  Loan payable                          180,000          -     180,000          -     180,000
  Share subscriptions received           20,000          -      20,000          -      20,000
  Advances from shareholder             (20,000)    10,000           -     10,000           -
                                      --------------------------------------------------------
                                        280,000     10,000     380,160     10,000     730,000
                                      --------------------------------------------------------


Cash Flows From
 Investing Activities
  Purchase of equipment                       -          -     (15,425)    (2,481)    (27,747)
  Patent acquisitions                  (180,000)         -    (200,000)         -    (220,000)
                                      --------------------------------------------------------
                                       (180,000)         -    (215,425)    (2,481)   (247,747)
                                      --------------------------------------------------------

(Decrease) Increase
 In Cash                                (32,485)      (800)   (103,831)   (23,445)     79,777

Cash,
 Beginning Of Period                    112,262        947     183,608     23,592           -
                                      --------------------------------------------------------

Cash,
End Of Period                         $  79,777   $    147   $  79,777   $    147   $  79,777
==============================================================================================

</TABLE>







                                       6


<PAGE>





                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

             CONSOLIDATED INTERIM STATEMENT OF STOCKHOLDERS' EQUITY

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)








<TABLE>
<CAPTION>


                                     COMMON STOCK
                            ----------------------------------
                                                   ADDITIONAL
                                                   PAID-IN
                                SHARES     AMOUNT  CAPITAL     DEFICIT     TOTAL
                            -----------------------------------------------------
<S>                         <C>         <C>      <C>       <C>         <C>
Shares issued for cash at
 $0.001 (May 2000)           7,500,000  $ 7,500  $      -  $       -   $   7,500
Shares issued for cash at
 $0.01 (June 2000)           4,000,000    4,000    36,000          -      40,000
Shares issued for cash at
 $0.10 (August 2000)            75,000       75     7,425          -       7,500
Net loss for the period              -        -         -    (17,927)    (17,927)
                            -----------------------------------------------------

Balance,
 August 31, 2000            11,575,000   11,575    43,425    (17,927)     37,073

Net loss
 for the year                        -        -         -    (74,348)    (74,348)
                            -----------------------------------------------------

Balance,
 August 31, 2001            11,575,000   11,575    43,425    (92,275)    (37,275)

Shares issued for cash
 at $0.50 (August 2002)        150,000      150    74,850          -      75,000
Shares issued for cash
 at $1.00 (August 2002)        300,000      300   299,700          -     300,000

Net loss for the year                -        -         -    (91,003)    (91,003)
                            -----------------------------------------------------

Balance, August 31, 2002    12,025,000   12,025   417,975   (183,278)    246,722

Shares issued for cash
 at $2.50 (February 2003)       40,000       40    99,960          -     100,000
Net loss for the period              -        -         -   (247,900)   (247,900)
                            -----------------------------------------------------

Balance,
 February 28, 2003          12,065,000  $12,065  $517,935  $(431,178)  $  98,822
                            =====================================================

</TABLE>

                                       7

<PAGE>



                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



1.     BASIS  OF  PRESENTATION

The unaudited consolidated financial statements as of February 28, 2003 included
herein have been prepared without audit pursuant to the rules and regulations of
the  Securities  and  Exchange  Commission.  Certain  information  and  footnote
disclosures  normally  included  in  financial statements prepared in accordance
with  United States generally accepted principles have been condensed or omitted
pursuant  to  such  rules  and  regulations.  In  the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary for a
fair  presentation  have  been  included.  It  is suggested that these financial
statements  be  read  in  conjunction with the August 31, 2002 audited financial
statements  and  notes  thereto.


2.     NATURE  OF  OPERATIONS

a)     Organization

The  Company was incorporated on May 26, 2000 in the State of Nevada, U.S.A.  On
December  31,  2002,  the Company changed its name from Coyote Ventures Corp. to
August  Biomedical  Corporation.

b)     Development  Stage  Activities

August  Biomedical  Corporation (the "Company") is currently a development stage
company  under  the  provisions  of  Statement of Financial Accounting Standards
("SFAS") No. 7.  The Company is engaged in the business of developing technology
related to cancer imaging systems and conducts business through its wholly owned
subsidiary,  August  Research  Corporation.

In  prior  years,  the Company had been primarily engaged in the acquisition and
exploration  of  mining  properties,  and was classified as an exploration stage
company.

c)     Going  Concern

The  accompanying  financial  statements have been prepared assuming the Company
will  continue  as  a  going  concern.


                                       8



<PAGE>

                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



2.     NATURE  OF  OPERATIONS  (Continued)

c)     Going  Concern  (Continued)

As  shown  in  the accompanying financial statements, the Company has incurred a
net  loss  of  $431,178 for the period from May 26, 2000 (inception) to February
28,  2003,  and  has  no sales.  The future of the Company is dependent upon its
ability  to  obtain  financing  and  upon  future profitable operations from the
development  of its technology.  Management has plans to seek additional capital
through  a  private  placement  and  public  offering  of its common stock.  The
financial  statements  do  not  include  any  adjustments  relating  to  the
recoverability  and  classification  of  recorded  assets, or the amounts of and
classification  of  liabilities that might be necessary in the event the Company
cannot  continue  in  existence.


3.     SIGNIFICANT  ACCOUNTING  POLICIES

The  financial  statements  of the Company have been prepared in accordance with
generally  accepted  accounting  principles  in  the  United  States.  Because a
precise  determination  of  many assets and liabilities is dependent upon future
events,  the  preparation  of  financial  statements  for  a  period necessarily
involves  the  use  of  estimates  which have been made using careful judgement.

The  financial  statements have, in management's opinion, been properly prepared
within  reasonable  limits  of  materiality  and  within  the  framework  of the
significant  accounting  policies  summarized  below:

a)     Consolidation

These  financial  statements  include  the  accounts  of  the  Company  and  its
wholly-owned  subsidiaries,  Coyote-Flint  Exploration Corp. and August Research
Corp.,  both  British  Columbia  corporations.

b)     Equipment

Equipment  is recorded at cost.  Amortization of office equipment and laboratory
equipment  is calculated on a straight-line basis at annual rates of 30% and 20%
respectively.


                                       9



<PAGE>

                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



3.     SIGNIFICANT  ACCOUNTING  POLICIES  (Continued)

c)     Intangible  Asset

The  Company continually monitors its intangible assets to determine whether any
impairment  has  occurred.  In  making  such determination with respect to these
assets,  the  Company  evaluates  the  performance  on an undiscounted cash flow
basis,  of  the  intangible  assets  or  group  of assets, which gave rise to an
asset's  carrying  amount.  Should  impairment  be  identified,  a loss would be
reported  to  the extent that the carrying value of the related intangible asset
exceeds  the  fair value of that intangible asset using the discounted cash flow
method.  The  Company has not amortized intangible assets as operations have not
commenced.

d)     Use  of  Estimates

The  preparation  of  financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of  assets  and  liabilities,  and disclosure of
contingent  assets  and liabilities at the date of the financial statements, and
the  reported amounts of revenues and expenses for the reporting period.  Actual
results  could  differ  from  these  estimates.

e)     Foreign  Currency  Translation

The  Company's  functional currency is the U.S. dollar.  Transactions in foreign
currency  are  translated  into  U.S.  dollars  as  follows:

     i)   monetary  items  at  the  rate  prevailing  at the balance sheet date;
     ii)  non-monetary  items  at  the  historical  exchange  rate;
     iii) revenue  and  expense  at  the  average  rate  in  effect  during  the
          applicable  accounting  period.


                                       10

<PAGE>


                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



3.     SIGNIFICANT  ACCOUNTING  POLICIES  (Continued)

f)     Stock  Based  Compensation

The  Company  accounts  for  stock  based  employee  and  director  compensation
arrangements  in  accordance  with  provisions  of  Accounting  Principles Board
("APB") Opinion No. 25 - "Accounting for Stock Issued to Employees", and related
interpretations,  and  complies with the disclosure provisions of SFAS No. 123 -
"Accounting  for  Stock  Based  Compensation".  Under  APB  No. 25, compensation
expense  is  based  on  the difference, if any, on the date the number of shares
receivable  is  determined,  between  the  estimated fair value of the Company's
stock  and  the  exercise  price  of options to purchase that stock. Stock based
compensation  arrangements  for  others  are recorded at their fair value as the
services  are  provided  and  the  compensation  earned.

g)     Income  Taxes

The  Company  has  adopted Statement of Financial Accounting Standards No. 109 -
"Accounting  for Income taxes" (SFAS 109).  This standard requires the use of an
asset  and  liability approach for financial accounting, and reporting on income
taxes.  If it is more likely than not that some portion or all of a deferred tax
asset  will  not  be  realized,  a  valuation  allowance  is  recognized.

h)     Basic  and  Diluted  Loss  Per  Share

In  accordance  with  SFAS  No.  128  - "Earnings Per Share", the basic loss per
common  share  is computed by dividing net loss available to common stockholders
by  the  weighted average number of common shares outstanding.  Diluted loss per
common  share is computed similar to basic loss per common share except that the
denominator  is increased to include the number of additional common shares that
would  have  been outstanding if the potential common shares had been issued and
if  the  additional  common  shares  were  dilutive.

I)     Mineral  Property  Option  Payments  and  Exploration  Costs

The  Company  expenses  all  costs related to the maintenance and exploration of
mineral claims in which it has secured exploration rights prior to establishment
of  proven  and probable reserves.  To date, the Company has not established the
commercial  feasibility  of  its exploration prospects, therefore, all costs are
being  expensed.

                                       11

<PAGE>


                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



4.     EQUIPMENT


<TABLE>
<CAPTION>



                                  FEBRUARY 28    AUGUST 31
                                      2003          2002
                                 --------------------------
<S>                              <C>            <C>
Office equipment                 $      2,481   $    2,481
Laboratory equipment                   25,265        9,841
                                 --------------------------
                                       27,746       12,322
Less:  Accumulated amortization        (3,328)      (1,331)
                                 --------------------------
                                 $     24,418   $   10,991
                                 ==========================
</TABLE>


5.     INTANGIBLE  ASSETS

(i)     Pursuant to a sale agreement dated August 16, 2002, the Company acquired
a  United  States  Patent for direct viewing of induced tissue fluorescence by a
human viewer through an endoscope (the "Technology").  The Technology is subject
to  a  royalty  of  0.75%  in  favour of the British Columbia Cancer Foundation.

     In  addition,  the  acquisition  is  subject  to  a provision requiring the
Company  to  complete debt or equity financing to raise net proceeds of $200,000
within  90  days of the agreement, and a further $800,000 within 180 days of the
agreement.  In  the  event  the Company does not raise the required funds within
the time required, the vendor may, at his option, reacquire the Technology for a
consideration  equal to the purchase price paid by the Company.  The Company has
fulfilled  the  first  provision  by  completing  a private placement of 300,000
common  shares  at  $1.00  per  share  for  gross  proceeds  of  $300,000.

(ii)     The  Company  has  acquired  certain  patents for cash consideration of
$200,000.


6.     LOAN  PAYABLE

Loan payable is a short term unsecured bridge financing repayable on the earlier
of  the  first major financing or August 30, 2003.  The loan is repayable in the
amount  of  $200,000  which  includes  interest.

                                       12


<PAGE>


                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



7.     SHARE  SUBSCRIPTIONS  RECEIVED

The Company approved the private placement of 3,000,000 units at $2.00 per unit.
Each  unit  will  consist  of  one  common  share and one warrant to purchase an
additional  common  share  at  $3.00  for  a  period  of  eighteen  months.


8.     CONTINGENCY

Intangible  Asset

The  Company's  intangible  asset has been acquired pursuant to a sale agreement
subject  to  certain financing conditions.  Although the Company has not met the
financing  conditions,  the vendor has not exercised his option to reacquire the
technology.


9.     STOCK  OPTION  PLAN

The  Company  adopted  a  stock  option  plan (the "Plan") pursuant to which the
directors may grant a maximum of 1,736,250 common stock options to officers, key
employees and consultants.  The Company granted 1,735,000 fully vested incentive
stock  options  allowing the holders to purchase one common share of the Company
at  $2.50  per  share  for  a  term  expiring  September  9,  2004.

The  following is a summary of the stock option activity during the period ended
February  28,  2003:

<TABLE>
<CAPTION>


                               WEIGHTED
                    NUMBER     AVERAGE
                    OF         EXERCISE
                    SHARES     PRICE
                   --------------------
<S>                <C>         <C>
Outstanding,
 August 31, 2002           -   $    -

Granted            1,735,000     2.50
Exercised            (40,000)   (2.50)
                   --------------------
Outstanding,
February 28, 2003  1,695,000   $ 2.50
                   ====================
</TABLE>


                                       13

<PAGE>

                          AUGUST BIOMEDICAL CORPORATION
                        (Formerly Coyote Ventures Corp.)
                          (A Development Stage Company)

               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2003
                                   (Unaudited)
                            (Stated in U.S. Dollars)



10.     RELATED  PARTY  TRANSACTIONS

During  the  period  ended  February  28,  2003, the Company incurred consulting
expenses  of  $63,498  to  directors  and  officers.

As  at February 28, 2003, the Company has $13,477 in accounts payable owing to a
director  and  officer.

                                       14

<PAGE>

Item  2.  Management's  Discussion  and  Analysis  or  Plan  of  Operations

Overview
--------

We  are  engaged  in  the  business  of developing medical devices to aid in the
detection and localization of abnormal tissue that may be linked to cancer.  Our
proprietary  technology will be incorporated in devices designed to allow direct
viewing  of  induced  tissue  fluorescence  to  help  identify pathology through
changes  in  the fluorescence signature of tissue.  We have identified that this
technology  could  be  used in the mouth, cervix, skin, colon, lung and bladder.
We  acquired  these technologies in August of 2002 and September of 2002, all of
which  is  more  particularly  described below under the heading "Acquisition of
Technology".  Initially,  our  plan  was  to  develop  a low cost direct imaging
device  that will allow dentists to better detect and localize abnormal areas of
the  mouth  more  cost  effectively than current alternatives.  Secondly, we are
continuing  to  develop  a  device for utilization of our proprietary technology
(Cerveyor(TM))  to improve the detection and screening of abnormal tissue on the
cervix.  Thirdly,  we  will  initiate research and  development programs for the
skin,  colon,  lung  and  bladder.

Acquisition  of  Technology
---------------------------

We acquired the CERVeyorTM Technology from Nicolas B MacKinnon (the "Vendor") by
an  agreement  dated  August  16, 2002 (the "Acquisition Agreement").  Under the
terms of the Acquisition Agreement we paid $20,000 (the "Purchase Price") to the
Vendor  to  acquire the CERVeyorTM Technology.  The Purchase Price is subject to
adjustment  in the event that a tax assessment of the Vendor attributes a higher
fair  market  value  to  the  CERVeyorTM  Technology  acquired.  The  CERVeyorTM
Technology  is  subject  to  a  royalty of .75% in favor of the British Columbia
Cancer  Foundation.  Under the terms of the Acquisition Agreement, Mr. MacKinnon
would  have  the  right to reacquire the CERVeyorTM Technology for $20,000 if we
failed to complete financing to raise net proceeds of $200,000 US within 90 days
of  the  date  of the Acquisition Agreement (which financing has been completed)
and  a  further  $800,000  US  within  180  days  of the date of the Acquisition
Agreement.  We  are presently in default of the Acquisition Agreement because we
have  failed  to  raise  $800,000 within 180 days of the date of the Acquisition
Agreement.  However, we are in discussions with Mr. MacKinnon to extend the date
of  the  financing  requirement.

We  entered into an option agreement dated September 9, 2002 (the "Biomax Option
Agreement")  with  Biomax Technologies (the "Optionor").  Under the terms of the
Biomax  Option  Agreement we paid $20,000 to acquire an option to acquire United
States  Patent  Number  6,021,344, a patent covering a fluorescence scope system
for  dermatologic  diagnosis  (the "ORALview Technology").  In order to exercise
the  option,  we  were  required to pay $180,000 US to the Optionor on or before
January  30,  2003.  We  have secured a loan that enabled us to pay the Optionor
and  exercise  this option.  The loan is a short term unsecured bridge financing
repayable  on  the earlier of the first major financing or August 20, 2003.  The
loan  including  interest  is repayable in the amount of $200,000   The ORALview
Technology  is  subject  to  royalties of 2.5% of gross revenues in favor of the
British  Columbia Cancer Agency and the original inventors consisting of a group
of  scientists  and doctors working with the British Columbia Cancer Agency.  We
believe the ORALview Technology will assist in expanding the applications of the
CERVeyorTM  Technology  particularly  for  oral  cancer  detection.



                                       15

<PAGE>


Plan  of  Operations:
---------------------

We  are currently in the development stage of technology and have forecasted the
expenditure  of  approximately  2.5  million  dollars during the next 12 months,
primarily  for  the  purpose  of:

     *    Expansion  of  our  internal  management  and research and development
          staff;

     *    Development  of  prototypes to provide proof of principal for both the
          oral  and  cervical  systems;

     *    Conducting  clinical  studies for the oral device in United States and
          Canada.

     *    Initiating  marketing  and  sales activities of the oral device in the
          United  States  and  Canada.

     *    Conducting  pilot  clinical  studies  for  the  Cerveyor(TM).

Following  successful  completion of these clinical trials, we will aggressively
pursue  strategic  marketing partners for the worldwide sale and distribution of
our  proprietary  technology.

We  do  not  anticipate  purchasing  any  real property or significant equipment
during  the  next  12  months.  We  plan  on  conducting our clinical studies in
partnership  with physicians who have an interest in our proprietary technology.
Our  clinical  studies  will  be  conducted  in  facilities  available  to those
physicians.

At  the  present  time  we  have no employees and primarily further our business
pursuits  through  the  use  of  consultants.  We  anticipate hiring several key
employees in early 2003.  Additional employees will be hired upon the successful
conclusion  of  our  clinical  studies  and  as  our  funding allows.  We cannot
determine  at  this  time  how  soon  additional  employees  will  be  hired.

At  February  28,  2003,  we had cash of $79,777.  During the three month period
ended  February  28,  2003,  we  incurred  expenses  of  $124,938.

The completion of our business plan for the next 12 months is contingent upon us
obtaining  additional  financing.  If  we  are  unable  to  obtain  additional
financing,  our  business  plan  will  be  significantly  delayed.  Without  any
additional  financing,  our  operations  can  continue  for  only  90   days.

To  meet  our projected cash flow needs, the board of directors has approved the
private  placement  of  3,000,000  million  units  at  $2.00  per unit for total
proceeds of $6,000,000.  Each unit will consist of one share of common stock and
one  warrant  to  purchase  one  share  of common stock at the exercise price of
$3.00,  subject  to  adjustment.  The  warrants will have an exercise term of 18
months.  Currently,  we  have  received  $20,000  in  share  subscriptions.

FORWARD  LOOKING  STATEMENTS

The  information  in  this discussion contains forward-looking statements within
the  meaning  of  Section  27A  of  the  Securities Act of 1933, as amended, and
Section  21E  of  the  Securities  Exchange  Act  of  1934,  as  amended.  These
forward-looking statements involve risks and uncertainties, including statements
regarding  our capital needs, business strategy and expectations. Any statements
contained herein that are not statements of historical facts may be


                                       16

<PAGE>


deemed  to  be  forward-looking  statements.  In  some  cases,  you can identify
forward-looking  statements  by  terminology  such  as  "may", "will", "should",
"expect",  "plan",  "intend",  "anticipate",  "believe",  "estimate", "predict",
"potential"  or  "continue",  the  negative  of  such  terms or other comparable
terminology. Actual events or results may differ materially. In evaluating these
statements,  you  should  consider various factors, including the risks outlined
below,  and,  from  time  to  time, in other reports we file with the SEC. These
factors  may  cause  the  our  actual  results  to  differ  materially  from any
forward-looking  statement.  We disclaim any obligation to publicly update these
statements,  or  disclose  any  difference  between its actual results and those
reflected  in  these  statements.  The  information  constitutes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995.


ITEM  3.     CONTROLS  AND  PROCEDURES.

As  required  by  Rule  13a-14  under  the  Securities Exchange Act of 1934 (the
"Exchange Act"), we carried out an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures within the 90 days prior
to  the  filing  date of this report.  This evaluation was carried out under the
supervision and with the participation of our Chief Executive Officer, Mr. Scott
C.  Houghton  and Chief Financial Officer, Ms. Korina Houghton.  Based upon that
evaluation,  our  Chief  Executive Officer and Chief Financial Officer concluded
that  our  disclosure  controls  and procedures are effective in timely alerting
management  to  material  information  relating  to  us  which is required to be
included in our periodic SEC filings.  There have been no significant changes in
our  internal  controls  or  in  other  factors  that could significantly affect
internal  controls  subsequent  to  the  date  we  carried  out  our evaluation.

Disclosure  controls  and  procedures are controls and other procedures that are
designed  to  ensure that information required to be disclosed our reports filed
or  submitted  under  the  Exchange  Act  is recorded, processed, summarized and
reported,  within  the  time  periods  specified  in the Securities and Exchange
Commission's  rules  and  forms.  Disclosure  controls  and  procedures include,
without  limitation, controls and procedures designed to ensure that information
required  to  be  disclosed  in  our  reports  filed  under  the Exchange Act is
accumulated  and  communicated  to  management,  including  our  Chief Executive
Officer  and  Chief  Financial  Officer,  to  allow  timely  decisions regarding
required  disclosure.

PART  II  -  OTHER  INFORMATION

Item  1.  Legal  Proceedings

We  are  not  a party to any material legal proceedings and to our knowledge, no
such  proceedings  are  threatened  or  contemplated.

Item  2.  Changes  in  Securities

We  did not complete any sales of our securities during the fiscal quarter ended
February  28,  2003.


Item  3.  Defaults  upon  Senior  Securities

None.


                                       17

<PAGE>



Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders

On  December  6,  2002, we furnished an information statement to stockholders to
inform them of the proposed majority shareholder action to amend our Articles of
Incorporation for the purpose of changing our name from Coyote Ventures Corp. to
August Biomedical Corporation.  Shareholder action approving the name change was
taken  on  or  about  December  26,  2002.


Item  5.  Other  Information

None.


Item  6.  Exhibits  and  Reports  on  Form  8-K.

EXHIBITS  REQUIRED  BY  ITEM  601  OF  REGULATION  SB

--------------------------------------------------------------------------------
Exhibit   ----------------------------------------------------------------------
Number    Description of Exhibit
------    ----------------------------------------------------------------------
99.1      Certification of Chief Executive Officer pursuant to 18 U.S.C. Section
          1350,  as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002  (1)

99.2      Certification of Chief Financial Officer pursuant to 18 U.S.C. Section
          1350,  as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002  (2)
--------------------------------------------------------------------------------
(1)     Filed  as  an  Exhibit  to  this  Quarterly  Report  on  Form  10-QSB
(2)     Filed  as  an  Exhibit  to  this  Quarterly  Report  on  Form  10-QSB
--------------------------------------------------------------------------------



REPORTS  ON  FORM  8-K

We  did not file any Current Reports on Form 8-K during the fiscal quarter ended
February  28,  2003.

                                       18

<PAGE>


                                   SIGNATURES

In  accordance with the requirements of the Securities and Exchange Act of 1934,
the  Registrant  has  duly  caused this report to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.

AUGUST  BIOMEDICAL  CORPORATION

Date:     April  21,  2003



By:  /s/ Scott  C.  Houghton
     ------------------------
     Scott  C.  Houghton
     President
     Principal  Executive  Officer
     Principal  Accounting  Officer

                                       19


<PAGE>


                                 CERTIFICATIONS

I,  Scott  C.  Houghton,  certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of August Biomedical
     Corporation;

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and

     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;

(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and

     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and


(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:   April  21,  2003           /s/ Scott  C.  Houghton
                                   ------------------------
                                   Scott  C.  Houghton
                                   Chief  Executive  Officer


<PAGE>



                                 CERTIFICATIONS

I,  Korina  Houghton,  certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of August Biomedical
     Corporation;

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and

     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;

(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and

     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and

(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.



Date:   April  21,  2003           /s/ Korina  Houghton
                                   -----------------------
                                   Korina  Houghton
                                   Chief  Financial  Officer